U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review Mar 29, 2019
Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System Mar 19, 2019
Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER Mar 4, 2019
Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products Jan 7, 2019
